Methopholine

Summary

Methopholine (CHEMBL2106915) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 345.9 Da · C20H24ClNO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106915
Name	Methopholine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	16538
Molecular formula	C20H24ClNO2
Molecular weight	345.9
InChIKey	YBCPYHQFUMNOJG-UHFFFAOYSA-N

SMILES: CN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)OC)OC

IUPAC name: 1-[2-(4-chlorophenyl)ethyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinoline

Also known as: ARC I-K-1, ARC-I-K-1, Methopholine, Metofolina, Metofoline, Metopholine, NIH 7672, NIH-7672, NSC-169889, Versidyne, METHOPHOLINE, metofoline

Patent coverage: 357 distinct patent families (1,449 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,447 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Amine oxidase [flavin-containing] A, Prostaglandin G/H synthase 2, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Nuclear receptor subfamily 1 group I member 2, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	6.11	AC50	770	nM	CHEMBL_ACT_25174788
OPRK1	5.92	AC50	1203	nM	CHEMBL_ACT_25129797
PTGS2	5.8	AC50	1600	nM	CHEMBL_ACT_25166574
NR1I2	5.44	AC50	3620	nM	CHEMBL_ACT_25188465

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).